## Edgar Filing: ENZO BIOCHEM INC - Form 8-K

ENZO BIOCHEM INC Form 8-K June 14, 2007

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest e	event reported): June 11, 2007		
Enzo Biochem, Inc.			
(Exact Name of Registrant as Specified in Its Charter)  New York  (State or Other Jurisdiction of Incorporation)			
		001-09974	13-2866202
		(Commission File Number)	(IRS Employer Identification No.)
527 Madison Avenue New York, New York	10022		
(Address of Principal Executive Offices)	(Zip Code)		
(212) 583-0100			
(Registrant's Telephone Number, Including Area Code)			
(Former Name or Former Address, if Changed Since Last Report)			
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):			
$ \_ $ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)			
$ \_ $ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)			
_  Pre-commencement communications pursua Exchange Act (17 CFR 240.14d-2(b))	ant to Rule 14d-2(b) under the		
_  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))			

(a) The following information, including the Exhibit attached hereto, is being

Item 2.02. Results of Operations and Financial Condition.

## Edgar Filing: ENZO BIOCHEM INC - Form 8-K

furnished pursuant to this Item 2.02 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

On June 11, 2007, Enzo Biochem, Inc., a New York corporation (the "Company"), issued a press release discussing its financial results for its third fiscal quarter ended April 30, 2007. A copy of the press release is furnished as Exhibit 99.1 to this report.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description

99.1 Press Release of Enzo Biochem, Inc., dated June 11, 2007, discussing financial results for third fiscal quarter ended

April 30, 2007.

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ENZO BIOCHEM, INC.

Date: June 13, 2007 By: /s/Elazar Rabbani

\_\_\_\_\_

Dr. Elazar Rabbani

Chairman of the Board and Chief

Executive Officer

### EXHIBIT INDEX

Exhibit No. Description

99.1 Press Release of Enzo Biochem, Inc., dated June 11, 2007, discussing financial results for third fiscal quarter ended

April 30, 2007.